Michelle Le, Lauren Khoury, Yang Lu, Connor Prosty, Maxime Cormier, Mathew P Cheng, Robert Fowler, Srinivas Murthy, Jennifer L Y Tsang, Moshe Ben-Shoshan, Elham Rahme, Shirin Golchi, Nandini Dendukuri, Todd C Lee, Elena Netchiporouk
BACKGROUND: Omalizumab is an anti-immunoglobulin E monoclonal antibody used to treat moderate to severe chronic idiopathic urticaria, asthma, and nasal polyps. Recent research suggested that omalizumab may enhance the innate antiviral response and have anti-inflammatory properties. OBJECTIVE: We aimed to investigate the efficacy and safety of omalizumab in adults hospitalized for coronavirus disease 2019 (COVID-19) pneumonia. METHODS: This was a phase II randomized, double blind, placebo-controlled trial comparing omalizumab with placebo (in addition to standard of care) in hospitalized patients with COVID-19...
April 2024: Open Forum Infectious Diseases